90Y-ibritumomab tiuxetan is a novel radioimmunotherapeutic agent recently approved for
the treatment of relapsed or refractory low-grade, follicular, or CD20+ transformed non …

From background physics and biological models to the latest imaging and treatment
modalities, the Handbook of Radiotherapy Physics: Theory and Practice covers all …

Treatment for nonresectable hepatocellular carcinoma (HCC) is palliative. The relatively
greater arteriolar density of hepatic tumors compared with normal liver suggests that …

Radioimmunotherapy (RIT) of lymphoma with Zevalin and Bexxar was approved by FDA in
2002 and 2003, respectively, for the treatment of relapsed or refractory CD20+ follicular B …

Background. Beta emitters, such as 90Y, are increasingly being used for cancer treatment.
However, beta emitters demand other precautions than gamma emitters during preparation …

In calculations of absorbed doses from radioactive patients, the activity distribution in such
patients is generally assumed to be an unattenuated point source and the dose to exposed …

High-energy beta emitters (yttrium-90, strontium-89 and phosphorus-32) are nowadays
increasingly used in therapeutic nuclear medicine. Beta particles and bremsstrahlung …

Purpose The purpose of this study was to estimate the possible external radiation dose to
other individuals from patients treated with Y-90 resin microspheres for unresectable …

Radiomicrosphere treatment involves the intrahepatic arterial administration of 90Y-resin or
90Y-glass microspheres. The microspheres are biocompatible, but not biodegradable, and …

Purpose The widespread interest in 90 Y internal radionuclide treatments has drawn
attention to the issue of radiation protection for staff. Our aim in this study was to identify …